The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | Could CAR-T potentially replace ASCT in NDMM?
Autologous stem cell transplantation (ASCT) has created a steep benchmark for other treatment options in newly diagnosed multiple myeloma (NDMM). Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, highlights the potential for CAR-T therapies to replace ASCT, but emphasizes the importance of fully understanding and optimizing these therapies before considering them as a substitute. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
